
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1479744/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Weight Loss through Lifestyle Intervention Improves Mobility in Older Adults. Gerontologist, The, 2022, 62, 931-941.	3.9	5
2	Costâ€effectiveness of ethanol lock prophylaxis to prevent central line–associated bloodstream infections in children with intestinal failure in the United States. Journal of Parenteral and Enteral Nutrition, 2022, 46, 324-329.	2.6	5
3	Effects of an Oncology Nurse-Led, Primary Palliative Care Intervention (CONNECT) on Illness Expectations Among Patients With Advanced Cancer. JCO Oncology Practice, 2022, 18, e504-e515.	2.9	2
4	Hope and advance care planning in advanced cancer: Is there a relationship?. Cancer, 2022, 128, 1339-1345.	4.1	17
5	Oneâ€year costâ€effectiveness of callosotomy vs vagus nerve stimulation for drugâ€resistant seizures in Lennoxâ€Gastaut Syndrome: A decision analytic model. Epilepsia Open, 2022, 7, 124-130.	2.4	12
6	Risk-stratification in febrile infants 29 to 60 days old: a cost-effectiveness analysis. BMC Pediatrics, 2022, 22, 79.	1.7	1
7	Investigation into the Cost-Effectiveness of Extended Posttraumatic Thromboprophylaxis. Journal of the American College of Surgeons, 2022, 234, 86-94.	0.5	0
8	ls Radiation Therapy Cost-Effective in the Positron Emission Tomography/Computed Tomography Era for Early-Stage Favorable Hodgkin Lymphoma With Alternative Payment Models?. Practical Radiation Oncology, 2022, 12, e135-e143.	2.1	1
9	Current practices in lipid emulsion utilization in the prevention and treatment of intestinal failure–associated liver disease: A survey of pediatric intestinal rehabilitation and transplant centers. Journal of Parenteral and Enteral Nutrition, 2022, 46, 1585-1592.	2.6	1
10	Cost-Effectiveness Analysis of Biological Signature DCISionRT Use for DCIS Treatment. Clinical Breast Cancer, 2021, 21, e271-e278.	2.4	5
11	Economic analysis of screening for subclinical rejection in kidney transplantation using protocol biopsies and noninvasive biomarkers. American Journal of Transplantation, 2021, 21, 186-197.	4.7	24
12	Microsimulation Model to Compare Enteral and Parenteral Iron Supplementation in Children With Intestinal Failure. Journal of Parenteral and Enteral Nutrition, 2021, 45, 810-817.	2.6	2
13	Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria. American Journal of Clinical Nutrition, 2021, 113, 172-178.	4.7	9
14	Costâ€Effectiveness of Primary Liver Transplantation Versus Hepatoportoenterostomy in the Management of Biliary Atresia in the United States. Liver Transplantation, 2021, 27, 711-718.	2.4	7
15	Cost-Effectiveness of Prophylactic Cranial Irradiation Versus MRI Surveillance for Extensive-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1186-1194.	0.8	2
16	Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis. Vaccine, 2021, 39, 4278-4282.	3.8	1
17	Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Î ^c value of information analysis. Vaccine, 2021, 39, 3608-3613.	3.8	1
18	Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors. American Journal of Preventive Medicine, 2021, 61, 28-36.	3.0	10

#	Article	IF	CITATIONS
19	Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin?. Clinical Drug Investigation, 2021, 41, 885-894.	2.2	3
20	Effect of an Oncology Nurse–Led Primary Palliative Care Intervention on Patients With Advanced Cancer. JAMA Internal Medicine, 2021, 181, 1451.	5.1	29
21	Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes. Journal of Comparative Effectiveness Research, 2021, 10, 1133-1141.	1.4	2
22	Imaging versus Intervention in Managing Small Unruptured Intracranial Aneurysms: A Cost-Effectiveness Analysis. Cerebrovascular Diseases, 2021, , 1-11.	1.7	2
23	A comparative cost-utility analysis of postoperative calcium supplementation strategies used in the current management of hypocalcemia. Surgery, 2020, 167, 137-143.	1.9	6
24	Cost-Effectiveness of Pneumococcal VaccinationÂand Uptake ImprovementÂPrograms in Underserved and General Population Adults Aged < 65ÂYears. Journal of Community Health, 2020, 45, 111-120.	3.8	7
25	Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria. American Journal of Clinical Nutrition, 2020, 111, 141-148.	4.7	16
26	Identification of Abusive Head Trauma in High-Risk Infants: AÂCost-Effectiveness Analysis. Journal of Pediatrics, 2020, 227, 176-183.e3.	1.8	4
27	Lungâ€5pecific Risk Factors Associated With Incident Hip Fracture in Current and Former Smokers. Journal of Bone and Mineral Research, 2020, 35, 1952-1961.	2.8	6
28	Costâ€Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations. Journal of the American Geriatrics Society, 2020, 68, 1271-1278.	2.6	7
29	Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations. American Journal of Preventive Medicine, 2020, 58, 487-495.	3.0	9
30	Financial Implications of 12-Month Dispensing of Oral Contraceptive Pills in the Veterans Affairs Health Care System. JAMA Internal Medicine, 2019, 179, 1201.	5.1	15
31	Exploring the potential public health benefits of universal influenza vaccine. Human Vaccines and Immunotherapeutics, 2019, 15, 2919-2926.	3.3	3
32	Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S Journal of the National Medical Association, 2019, 111, 540-545.	0.8	11
33	Comparing Microvascular Decompression with Gamma Knife Radiosurgery for Trigeminal Neuralgia. A Cost-Effectiveness Analysis. World Neurosurgery, 2019, 125, 207-216.	1.3	6
34	Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50–64†years compared to the US general population. Vaccine, 2019, 37, 2026-2033.	3.8	12
35	Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis. American Journal of Preventive Medicine, 2019, 56, e135-e141.	3.0	4
36	Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non–Small Cell Lung Cancer Based on Mutational Status. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 837-844.	1.3	4

#	Article	IF	CITATIONS
37	An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis. Human Vaccines and Immunotherapeutics, 2019, 15, 863-872.	3.3	9
38	Cost-Effectiveness of a Radio Frequency Hemostatic Sealer (RFHS) in Adult Spinal Deformity Surgery. World Neurosurgery, 2019, 122, 171-175.	1.3	3
39	Cost-Utility of Antimicrobial Prophylaxis for Treatment of Children With Vesicoureteral Reflux. Frontiers in Pediatrics, 2019, 7, 530.	1.9	10
40	Interventionist training and intervention fidelity monitoring and maintenance for CONNECT, a nurse-led primary palliative care in oncology trial. Contemporary Clinical Trials Communications, 2018, 10, 57-61.	1.1	17
41	Cost-Effectiveness Analysis of a Military Hearing Conservation Program. Military Medicine, 2018, 183, e547-e553.	0.8	10
42	Cost-Effectiveness of Single Versus Confirmatory Urinalysis in the Evaluation of Asymptomatic Microhematuria. Urology Practice, 2018, 5, 427-432.	0.5	0
43	Impact of seasonal influenza vaccination in the presence of vaccine interference. Vaccine, 2018, 36, 853-858.	3.8	7
44	Exercise, Manual Therapy, and Booster Sessions in Knee Osteoarthritis: Cost-Effectiveness Analysis From a Multicenter Randomized Controlled Trial. Physical Therapy, 2018, 98, 16-27.	2.4	23
45	Costâ€effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. Head and Neck, 2018, 40, 1743-1751.	2.0	7
46	Comparing the Air Medical Prehospital Triage Score With Current Practice for Triage of Injured Patients to Helicopter Emergency Medical Services. JAMA Surgery, 2018, 153, 261.	4.3	18
47	Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. Journal of Vascular Surgery, 2018, 67, 343-352.	1.1	30
48	A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 290-298.	4.5	1
49	Costâ€effectiveness analysis of two caries prevention methods in the first permanent molar in children. Journal of Public Health Dentistry, 2018, 78, 118-126.	1.2	12
50	Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage. Anesthesiology, 2018, 128, 328-337.	2.5	45
51	Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults. Innovation in Aging, 2018, 2, igy035.	0.1	3
52	Mobility and Vitality Lifestyle Program (MOVE UP): A Community Health Worker Intervention for Older Adults With Obesity to Improve Weight, Health, and Physical Function. Innovation in Aging, 2018, 2, igy012.	0.1	13
53	Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Advances, 2018, 2, 1792-1798.	5.2	56
54	Cost-Effectiveness of Ventricular Assist Device Destination Therapy for Advanced Heart Failure in Duchenne Muscular Dystrophy. Pediatric Cardiology, 2018, 39, 1242-1248.	1.3	8

#	Article	IF	CITATIONS
55	Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 2564-2572.	2.3	6
56	Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Value in Health, 2018, 21, 1365-1372.	0.3	8
57	Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. American Journal of Cardiovascular Drugs, 2018, 18, 317-325.	2.2	10
58	Cost-effectiveness of increasing vaccination in high-risk adults aged 18–64ÂYears: a model-based decision analysis. BMC Infectious Diseases, 2018, 18, 52.	2.9	14
59	A cluster randomized trial of a primary palliative care intervention (CONNECT) for patients with advanced cancer: Protocol and key design considerations. Contemporary Clinical Trials, 2017, 54, 98-104.	1.8	31
60	Use of personal protective equipment among health care personnel: Results of clinical observations and simulations. American Journal of Infection Control, 2017, 45, 17-23.	2.3	97
61	Potential Consequences of Not Using Live Attenuated Influenza Vaccine. American Journal of Preventive Medicine, 2017, 53, 500-503.	3.0	1
62	Supraorbital Versus Endoscopic Endonasal Approaches for Olfactory Groove Meningiomas: A Cost-Minimization Study. World Neurosurgery, 2017, 105, 126-136.	1.3	22
63	Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study. American Journal of Epidemiology, 2017, 185, 822-831.	3.4	13
64	Reply to: Estimating the Full Value of Highâ€Dose Influenza Vaccine. Journal of the American Geriatrics Society, 2017, 65, 2111-2112.	2.6	1
65	Costâ€Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. Journal of the American Geriatrics Society, 2017, 65, 763-768.	2.6	11
66	Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults. Vaccine, 2017, 35, 5708-5713.	3.8	11
67	Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study. Vaccine, 2017, 35, 3974-3981.	3.8	14
68	Hypertension with unsatisfactory sleep health (HUSH): study protocol for a randomized controlled trial. Trials, 2017, 18, 256.	1.6	13
69	A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children. Journal of Pediatrics, 2017, 189, 54-60.e3.	1.8	27
70	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thrombosis Research, 2017, 150, 123-130.	1.7	22
71	Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old. Human Vaccines and Immunotherapeutics, 2017, 13, 2207-2212.	3.3	4
72	Promoting Organ Donor Registries Through Public Education. Transplantation, 2016, 100, 1332-1338.	1.0	10

#	Article	IF	CITATIONS
73	Costâ€effectiveness of new antiviral regimens for treatmentâ€naÃ⁻ve U.S. veterans with hepatitis C. Hepatology, 2016, 63, 428-436.	7.3	33
74	Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value in Health, 2016, 19, 326-334.	0.3	30
75	Cost effectiveness of an internet-delivered lifestyle intervention in primary care patients with high cardiovascular risk. Preventive Medicine, 2016, 87, 103-109.	3.4	22
76	Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy. Value in Health, 2016, 19, 537-543.	0.3	4
77	Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1175-1183.	0.8	24
78	Cost Effectiveness of Influenza Vaccine for U.S. Children. American Journal of Preventive Medicine, 2016, 51, 309-317.	3.0	11
79	Costâ€Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. Journal of the American Geriatrics Society, 2016, 64, 2126-2131.	2.6	34
80	Cost-effectiveness of workplace wellness to prevent cardiovascular events among U.S. firefighters. BMC Cardiovascular Disorders, 2016, 16, 229.	1.7	8
81	The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infectious Diseases, 2016, 16, 655.	2.9	33
82	Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2–8 Years in the U.S American Journal of Preventive Medicine, 2016, 50, 600-608.	3.0	8
83	Automated Communication Tools and Computer-Based Medication Reconciliation to Decrease Hospital Discharge Medication Errors. American Journal of Medical Quality, 2016, 31, 315-322.	0.5	11
84	Decreasing Trends of Healthcare-Associated Infections: Multifactorial Synergy. Infection Control and Hospital Epidemiology, 2015, 36, 656-657.	1.8	0
85	Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers. Oncology Research, 2015, 22, 311-319.	1.5	2
86	Cost-Effectiveness of Pediatric Heart Transplantation Across a Positive Crossmatch for High Waitlist Urgency Candidates. American Journal of Transplantation, 2015, 15, 2978-2985.	4.7	5
87	Cost-Effectiveness Analysis of Single Fraction ofÂStereotactic Body Radiation Therapy Compared With Single Fraction of External Beam Radiation Therapy for Palliation of Vertebral Bone Metastases. International Journal of Radiation Oncology Biology Physics, 2015, 91, 556-563.	0.8	44
88	Comparison of Listing Strategies for Allosensitized Heart Transplant Candidates Requiring Transplant at High Urgency: A Decision Model Analysis. American Journal of Transplantation, 2015, 15, 427-435.	4.7	24
89	Cost-effectiveness analysis of 3D image-guided brachytherapy compared with 2D brachytherapy in the treatment of locally advanced cervical cancer. Brachytherapy, 2015, 14, 29-36.	0.5	40
90	Cost-Effectiveness of Decision Support Strategies in Acute Bronchitis. Journal of General Internal Medicine, 2015, 30, 1505-1510.	2.6	9

#	Article	IF	CITATIONS
91	Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer, 2015, 15, 62.	2.6	69
92	Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Infection Control and Hospital Epidemiology, 2015, 36, 438-444.	1.8	63
93	Economic Analysis of Universal Active Surveillance Screening for Methicillin-Resistant <i>Staphylococcus aureus</i> : Perspective Matters. Infection Control and Hospital Epidemiology, 2015, 36, 14-16.	1.8	4
94	Determining the cost–effectiveness of adult pneumococcal vaccination strategies. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 1-4.	1.4	4
95	Three Cost-utility Analyses of Screening for Intracranial Hemorrhage in Neonates With Hemophilia. Journal of Pediatric Hematology/Oncology, 2014, 36, 474-479.	0.6	4
96	Cost-Effectiveness of Routine Surveillance Endomyocardial Biopsy After 12 Months Post–Heart Transplantation. Circulation: Heart Failure, 2014, 7, 807-813.	3.9	24
97	Probability of pregnancy after sterilization: a comparison of hysteroscopic versus laparoscopic sterilization. Contraception, 2014, 90, 174-181.	1.5	34
98	Cost-Effectiveness of Procalcitonin-Guided Antibiotic Therapy for Outpatient Management of Acute Respiratory Tract Infections in Adults. Journal of General Internal Medicine, 2014, 29, 579-586.	2.6	35
99	Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States. BMC Public Health, 2014, 14, 718.	2.9	9
100	Transoral Robotic Surgery and the Unknown Primary: A Costâ€Effectiveness Analysis. Otolaryngology - Head and Neck Surgery, 2014, 150, 976-982.	1.9	47
101	Managing mesh exposure following vaginal prolapse repair: a decision analysis comparing conservative versus surgical treatment. International Urogynecology Journal, 2013, 24, 119-125.	1.4	10
102	Cost-Effectiveness of Procalcitonin-Guided Antibiotic Use in Community Acquired Pneumonia. Journal of General Internal Medicine, 2013, 28, 1157-1164.	2.6	25
103	Cost-Effectiveness of a Program to Eliminate Disparities in Pneumococcal Vaccination Rates in Elderly Minority Populations: An Exploratory Analysis. Value in Health, 2013, 16, 311-317.	0.3	7
104	Incremental Cost Effectiveness of Pharmacist-Managed Erythropoiesis-Stimulating Agent Clinics for Non-Dialysis-Dependent Chronic Kidney Disease Patients. Applied Health Economics and Health Policy, 2013, 11, 653-660.	2.1	12
105	Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine, 2013, 31, 3950-3956.	3.8	33
106	Potential unintended pregnancies averted and cost savings associated with a revised Medicaid sterilization policy. Contraception, 2013, 88, 691-696.	1.5	31
107	Anticoagulation duration in heterozygous factor V Leiden: A decision analysis. Thrombosis Research, 2013, 132, 724-728.	1.7	2
108	Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A U.S. perspective. Thrombosis Research, 2013, 132, 647-651.	1.7	35

#	Article	IF	CITATIONS
109	Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in U.S. Older Adults. American Journal of Preventive Medicine, 2013, 44, 373-381.	3.0	39
110	Costâ€effectiveness of endoscopic sphenopalatine artery ligation versus nasal packing as firstâ€line treatment for posterior epistaxis. International Forum of Allergy and Rhinology, 2013, 3, 563-566.	2.8	34
111	Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder. American Journal of Managed Care, 2013, 19, e55-63.	1.1	5
112	Cost-effectiveness of pneumococcal and influenza vaccination standing order programs. American Journal of Managed Care, 2013, 19, e30-7.	1.1	6
113	Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide Vaccine. JAMA - Journal of the American Medical Association, 2012, 307, 804-12.	7.4	115
114	Cost Impact of Molecular Testing for Indeterminate Thyroid Nodule Fine-Needle Aspiration Biopsies. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1905-1912.	3.6	131
115	The Cost-Effectiveness of Immediate Treatment, Percutaneous Biopsy and Active Surveillance for the Diagnosis of the Small Solid Renal Mass: Evidence From a Markov Model. Journal of Urology, 2012, 187, 39-43.	0.4	42
116	Impact of Pharmacist-Managed Erythropoiesis-Stimulating Agents Clinics for Patients With Non–Dialysis-Dependent CKD. American Journal of Kidney Diseases, 2012, 60, 371-379.	1.9	26
117	Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation. Thrombosis and Haemostasis, 2012, 108, 303-310.	3.4	10
118	A costâ€effectiveness analysis of positron emission tomographyâ€computed tomography surveillance versus upâ€front neck dissection for management of the neck for N2 disease after chemoradiotherapy. Laryngoscope, 2012, 122, 311-314.	2.0	22
119	Cost Effectiveness of Rivaroxaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism Blood, 2012, 120, 3177-3177.	1.4	1
120	Information primary care physicians want to receive about their hospitalized patients. Family Medicine, 2012, 44, 425-30.	0.5	5
121	Incremental cost-effectiveness of various monthly doses of vardenafil. Value in Health, 2011, 14, 97-101.	0.3	5
122	The potential economic value of a hookworm vaccine. Vaccine, 2011, 29, 1201-1210.	3.8	30
123	Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups. Vaccine, 2011, 29, 3525-3530.	3.8	18
124	Reliability of Laparoscopic Compared With Hysteroscopic Sterilization at 1 Year. Obstetrics and Gynecology, 2011, 118, 273-279.	2.4	27
125	Economic value of norovirus outbreak control measures in healthcare settings. Clinical Microbiology and Infection, 2011, 17, 640-646.	6.0	29
126	The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA. Clinical Microbiology and Infection, 2011, 17, 1717-1726.	6.0	21

#	Article	IF	CITATIONS
127	Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecologic Oncology, 2011, 122, 473-478.	1.4	37
128	The costâ€effectiveness of communityâ€based screening for oral cancer in highâ€risk males in the United States: A Markov decision analysis approach. Laryngoscope, 2011, 121, 952-960.	2.0	36
129	Herpes Zoster Vaccine and Older Adults. JAMA - Journal of the American Medical Association, 2011, 305, 1410.	7.4	1
130	Cost-Effectiveness of Implementing the Chronic Care Model for Diabetes Care in a Military Population. Journal of Diabetes Science and Technology, 2011, 5, 501-513.	2.2	17
131	Costâ€ldentification Analysis of Total Laryngectomy. Otolaryngology - Head and Neck Surgery, 2011, 144, 220-224.	1.9	12
132	InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence. Female Pelvic Medicine and Reconstructive Surgery, 2011, 17, 199-203.	1.1	16
133	Anticoagulation in Ambulatory Cancer Patients. Blood, 2011, 118, 2071-2071.	1.4	Ο
134	Retropubic and transobturator midurethral slings: a decision analysis to compare outcomes including efficacy and complications. International Urogynecology Journal, 2010, 21, 787-793.	1.4	22
135	Cost-Utility Analysis of von Willebrand Disease Screening in Adolescents with Menorrhagia. Journal of Pediatrics, 2010, 157, 456-460.e1.	1.8	19
136	A cost-effectiveness analysis of coagulation testing prior to tonsillectomy and adenoidectomy in children. Pediatric Blood and Cancer, 2010, 55, 1153-1159.	1.5	34
137	Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers. Clinical Microbiology and Infection, 2010, 16, 1740-1746.	6.0	26
138	To Test or to Treat? An Analysis of Influenza Testing and Antiviral Treatment Strategies Using Economic Computer Modeling. PLoS ONE, 2010, 5, e11284.	2.5	42
139	Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine. CNS Drugs, 2010, 24, 695-712.	5.9	19
140	Universal Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Surveillance for Adults at Hospital Admission: An Economic Model and Analysis. Infection Control and Hospital Epidemiology, 2010, 31, 598-606.	1.8	63
141	Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients. Journal of Vascular Surgery, 2010, 52, 1537-1545.e2.	1.1	30
142	Cost-Effectiveness of Implantable Cardioverter-Defibrillators inÂChildren With Dilated Cardiomyopathy. Journal of Cardiac Failure, 2010, 16, 734-741.	1.7	22
143	The potential economic value of a Staphylococcus aureus vaccine for neonates. Vaccine, 2010, 28, 4653-4660.	3.8	8
144	Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine, 2010, 28, 5952-5959.	3.8	34

#	Article	IF	CITATIONS
145	Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine, 2010, 28, 7620-7625.	3.8	30
146	Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine, 2010, 28, 7731-7736.	3.8	46
147	Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement. Pharmacoeconomics, 2010, 28, 521-538.	3.3	34
148	The Authors' Reply. Pharmacoeconomics, 2010, 28, 782-784.	3.3	1
149	Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic. American Journal of Managed Care, 2010, 16, 200-6.	1.1	9
150	Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007. Preventing Chronic Disease, 2010, 7, A109.	3.4	31
151	Economics of influenza vaccine administration timing for children. American Journal of Managed Care, 2010, 16, e75-e85.	1.1	18
152	Using Thrombophilia Testing to Determine Anticoagulation Duration in Pediatric Thrombosis is not Cost-Effective. Journal of Pediatrics, 2009, 155, 100-104.	1.8	23
153	Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis. International Urogynecology Journal, 2009, 20, 933-938.	1.4	16
154	Costâ€Effectiveness of Screening for Unhealthy Alcohol Use with %Carbohydrate Deficient Transferrin: Results From a Literatureâ€Based Decision Analytic Computer Model. Alcoholism: Clinical and Experimental Research, 2009, 33, 1440-1449.	2.4	15
155	Direct Paramedic Transport of Acute Myocardial Infarction Patients to Percutaneous Coronary Intervention Centers: A Decision Analysis. Annals of Emergency Medicine, 2009, 53, 233-240.e5.	0.6	11
156	A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age) Tj ETQq0 0	0 rggT /O	verlock 10 Tf
157	Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis. Vaccine, 2009, 27, 3159-3164.	3.8	10
158	The timing of influenza vaccination for older adults (65 years and older). Vaccine, 2009, 27, 7110-7115.	3.8	27
159	Should Vascular Surgery Patients Be Screened Preoperatively for Methicillin-Resistant <i>Staphylococcus aureus</i> ?. Infection Control and Hospital Epidemiology, 2009, 30, 1158-1165.	1.8	28
160	Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis. Vaccine, 2008, 26, 1420-1431.	3.8	59
161	Economic Evaluation of Standing Order Programs for Pneumococcal Vaccination of Hospitalized Elderly Patients. Infection Control and Hospital Epidemiology, 2008, 29, 385-394.	1.8	33

¹⁶²Quality of Life Utilities for Pelvic Inflammatory Disease Health States. Sexually Transmitted Diseases,
2008, 35, 307-311.1.733

#	Article	IF	CITATIONS
163	Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use?. Thrombosis and Haemostasis, 2008, 100, 447-452.	3.4	21
164	Cost Effectiveness Strategy to Predict Postoperative Bleeding in Von Willebrand Disease Blood, 2008, 112, 1295-1295.	1.4	0
165	A Cost-Effectiveness Analysis of Coagulation Testing Prior to Tonsillectomy and Adenoidectomy in Children Blood, 2008, 112, 1294-1294.	1.4	0
166	Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Thrombosis and Haemostasis, 2008, 100, 447-52.	3.4	11
167	Cost-Effectiveness of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Clinical Infectious Diseases, 2007, 44, 1280-1288.	5.8	125
168	Cost Comparisons between Home- and Clinic-Based Testing for Sexually Transmitted Diseases in High-Risk Young Women. Infectious Diseases in Obstetrics and Gynecology, 2007, 2007, 1-5.	1.5	26
169	Hospitalization for Pelvic Inflammatory Disease: A Cost-Effectiveness Analysis. Sexually Transmitted Diseases, 2007, 34, 108-112.	1.7	22
170	Sequential Medication Strategies for Postherpetic Neuralgia: A Cost-Effectiveness Analysis. Journal of Pain, 2007, 8, 396-404.	1.4	31
171	Cost-Effectiveness of Alternative Outpatient Pelvic Inflammatory Disease Treatment Strategies. Sexually Transmitted Diseases, 2007, 34, 960-966.	1.7	12
172	A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatric Blood and Cancer, 2007, 48, 173-180.	1.5	32
173	Time from Sexually Transmitted Infection Acquisition to Pelvic Inflammatory Disease Development: Influence on the Cost-Effectiveness of Different Screening Intervals. Value in Health, 2007, 10, 358-366.	0.3	21
174	Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sexually Transmitted Diseases, 2007, 34, 960-6.	1.7	10
175	Prediction of Pelvic Inflammatory Disease Among Young, Single, Sexually Active Women. Sexually Transmitted Diseases, 2006, 33, 137-142.	1.7	51
176	Teaching Medical Decision Modeling: A Qualitative Description of Student Errors and Curriculum Responses. Medical Decision Making, 2006, 26, 583-588.	2.4	1
177	Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism. Chest, 2005, 128, 1601-1610.	0.8	87
178	Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thrombosis and Haemostasis, 2005, 93, 592-599.	3.4	25
179	Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. American Journal of Medicine, 2005, 118, 625-635.	1.5	31
180	Quality-of-Life Utility Values for???Erectile Function and Sildenafil Treatment. Clinical Drug Investigation, 2005, 25, 99-105.	2.2	22

#	Article	IF	CITATIONS
181	Treatment of Acute Childhood Idiopathic Thrombocytopenic Purpura (ITP): A Cost-Utility Analysis Blood, 2005, 106, 1337-1337.	1.4	1
182	Pharmacoeconomics of antiviral therapies for Herpes zoster infections. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 527-534.	1.4	0
183	Cost-effectiveness of newer treatment strategies for influenza. American Journal of Medicine, 2002, 113, 300-307.	1.5	84
184	The Cost-Effectiveness of Sildenafil. Annals of Internal Medicine, 2000, 132, 933.	3.9	62
185	Antiviral Therapies for Herpes Zoster Infections. Pharmacoeconomics, 2000, 18, 95-104.	3.3	29
186	Are Current Recommendations for Antiviral Therapy of Herpes Zoster Cost-Effective?. Journal of General Internal Medicine, 2000, 15, 4-4.	2.6	1
187	Cost Effectiveness of Early Treatment with Oral Aciclovir in Adult Chickenpox*. Pharmacoeconomics, 1998, 13, 645-651.	3.3	5
188	Cost Effectiveness of Newer Antiviral Agents for Herpes Zoster: Is the Evidence Spotty?. Journal of Infectious Diseases, 1998, 178, S85-S90.	4.0	11
189	AIDS-Associated Non-Hodgkin's Lymphomas as Primary and Secondary AIDS Diagnoses in Hemophiliacs. Journal of Acquired Immune Deficiency Syndromes, 1996, 13, 78-86.	0.3	3
190	Characterization of a factor IX variant with a glycine207 to glutamic acid mutation. Blood, 1994, 84, 1866-1873.	1.4	7
191	Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA. Infectious Diseases and Therapy, 0, , .	4.0	2